Furthermore, two studies (NeoPAL27 and CORALLEEN28) demonstrated comparable efficacy and superior safety of neoadjuvant CDK4/6 inhibitors + ET for high-risk luminal breast cancer compared to conventional neoadjuvant chemotherapy regimens. This evidence concerns the gene CDK4 and breast cancer.